scholarly journals Parathyroid hormone response to severe vitamin D deficiency is associated with femoral neck bone mineral density: an observational study of 405 women with hip-fracture

HORMONES ◽  
2017 ◽  
Vol 15 (4) ◽  
pp. 527-533 ◽  
Author(s):  
Marco Di Monaco ◽  
Carlotta Castiglioni ◽  
Rosa Tappero
2020 ◽  
Vol 30 (12) ◽  
pp. 4995-5000
Author(s):  
Mustafa Raoof ◽  
Ingmar Näslund ◽  
Eva Rask ◽  
Eva Szabo

Abstract Background The aim of the present study was to study longitudinal changes in bone mineral density (BMD), vitamin D, and parathyroid hormone (PTH) levels in females over a 10-year period after laparoscopic Roux-en-Y gastric bypass (LRYGB). Methods Twenty-three women, mean age 43.4 ± 8.7 years and mean body mass index (BMI) 44.6 ± 5.17 kg/m2 at baseline, were included. BMD, BMI, S-calcium, S-25(OH)-vitamin D, and fP-PTH were measured preoperatively and 2, 5, and 10 years postoperatively. Results Ten years after surgery, BMD of the spine and femoral neck decreased by 20% and 25%, respectively. Changes in serum levels of vitamin D, PTH, and calcium over the same period were small. Conclusion After LRYGB with subsequent massive weight loss, a large decrease in BMD of the spine and femoral neck was seen over a 10-year postoperative period. The fall in BMD largely occurred over the first 5 years after surgery.


2020 ◽  
Vol 4 (Supplement_1) ◽  
Author(s):  
Aneeta J Joseph ◽  
Jesus L Penabad ◽  
Antonio Pinero-Pilona

Abstract Introduction: Teriparatide, a parathyroid hormone analog, is an important anabolic agent approved by the U.S. Food and Drug Administration to increase bone mineral density in osteoporotic patients. Parathyroid hormone (PTH) regulates calcium, phosphate, and active vitamin-D metabolites.The amino terminal peptide fragments of PTH has been known to increase bone mass and are being used in clinical practice for osteoporosis management (1). Current literature shows the efficacy of teriparatide in increasing bone density of lumbar spine and femoral neck, and decreasing the risk of vertebral and non-vertebral fractures both in postmenopausal women and men. It is also known to prevent fractures in patients with osteoporosis and promote healing of fractures (2). Case Description: A 79-year-old Hispanic female with history of osteopenia and major lumbar spine wedge compression fractures presented to our clinic for consultation. She was on ibandronate for the past four months and was having symptoms of pill esophagitis. Her last bone mineral density done on August 2017 revealed T-score of -2.5 at the lumbar spine, -1.5 at the left femoral neck, and 3.3% bone loss on the left femoral head. Rather than being started on teriparatide, zoledronic acid, or denosumab, she continued ibandronate along with calcium and vitamin D. Two months after the initial consultation, she sustained a traumatic fracture of the posterior arch and body of C2 bilaterally following a motor vehicle accident. There were discussions about starting anabolic treatment, as serial imaging did not show any significant improvement in the healing process despite the use of a collar. Two months after sustaining C2 fracture, she was started on teriparatide. Repeat cervical spine x-ray three months later showed complete healing of the C2 fracture. Discussion: There are a limited number of cases reported in regards to teriparatide induced healing of non-osteoporotic fractures (3). Our case is one of the very few reported to have shown complete radiographic and clinical healing of a traumatic, non-osteoporotic fracture after use of teriparatide for 12 weeks.


2011 ◽  
Vol 6 (1-2) ◽  
pp. 209-213 ◽  
Author(s):  
Noortje M. Rabelink ◽  
Hans M. Westgeest ◽  
Nathalie Bravenboer ◽  
Maarten A. J. M. Jacobs ◽  
Paul Lips

2021 ◽  
pp. 45-52
Author(s):  
N.S. Shevchenko ◽  
◽  
L.F. Bogmat ◽  
Yu.V. Khadzhinova ◽  
◽  
...  

Osteopenia (osteopenic syndrome) and osteoporosis (OP) are among the frequent and highly disabling conditions that accompany the development of rheumatic diseases (RD), including juvenile idiopathic arthritis (JIA). Changes in the requirements for the diagnosis and treatment of children with JIA according to the treatment strategy to achieve the goal (treat to target) have led to a decrease in the frequency of development and manifestations of OP in patients with RD. The condition of bone tissue in children with JIA, against the background of modern therapy and in conditions of widespread vitamin D deficiency requires further study. Purpose — to study bone mineral density (BMD) in children with JIA in modern disease management and to identify adverse factors for the development of OP among clinical signs. Materials and methods. We examined 35 children with JIA aged 7 to 17 years, mostly female (77.1%), with oligo (25.7)%, poly (60.0%) and undifferentiated (14.3%) option, 53.4% of whom have not yet received basic therapy. All patients underwent BMD by dual-energy X-ray absorptiometry on a bone densitometer Explorer QD W (Hologic), parathyroid hormone (PTH), 25-hydroxyvitamin D [25(OH)D], total and ionized calcium and phosphorus in syvo. The control group consisted of 12 healthy children of the same age with a normal level of 25(OH)D. Results. The mean level of vitamin D in the serum of children in the main group was 20.41±1.35 ng/ml, which was significantly lower than in the control group (30.03±2.53 ng/ml, p<0.05); the frequency of low levels of vitamin D reached 88.57%. The content of calcium and phosphorus in the blood did not deviate from the normative values, despite the widespread deficiency of vitamin D. 98.37% of patients had normal PTH values, the average level in the blood was 30.43±0.90 pg/ml. The content of PTH was the highest in non-differential arthritis (34.33±1.80 pg/ml), the lowest in the oligoarticular variant (28.36±1.43 pg/ml, p<0.05). PTH concentrations correlated with vitamin D levels (r=-0.41; p<0.05) and were independent of patient gender and disease activity. The frequency of decreased BMD was 28.57% of the surveyed children. The prevalence of osteopenia was the same in different variants of arthritis and did not depend on the sex and age of patients, positivity in the RF. Osteopenic syndrome was significantly more common in ANA-positive JIA than in ANA-negative variant (46.15% vs. 18.18%; pϕ<0.05). The condition of bone tissue (Z-criteria) depended on BMI (r=0.33; p<0.05), disease activity on the JADAS scale (r=0.35; p<0.04), the number of active joints (r=0.34; p<0.05); ANA level (r=-0.34; p<0.05). In the group of children with osteopenic syndrome, BMD correlated with the duration of the disease (r=-0.67; p<0.05), the number of active joints (r=-0.62; p<0.05), the level of blood phosphorus 0.74; p<0.05) and the sum of points on the JADAS scale (r=0.59; p<0.05). In the group of children with preserved BMD, the spectrum of correlations was supplemented by indicators of vitamin D status (r=-0.33; p<0.05) and BMI (r=-0.40; p<0.05). Conclusions. In children with JIA, the incidence of osteopenia is 28.57% with vitamin D deficiency in 88.57% of patients, preserved levels of total calcium, phosphorus and PTH in the blood. Decreased BMD in the early stages of JIA is associated with a younger age of patients and the age of onset of the disease, increased prevalence of joint syndrome, inflammatory and serological activity of the disease, ionized calcium and blood phosphorus, PTH levels and decreased vitamin D (р<0,001). The research was carried out in accordance with the principles of the Helsinki Declaration. The study protocol was approved by the Local Ethics Committee of these Institutes. The informed consent of the patient was obtained for conducting the studies. No conflict of interest was declared by the authors. Key words: bone mineral density; juvenile idiopathic arthritis; osteopenia; 25-OH-vitamin D; parathyroid hormone.


2017 ◽  
Vol 24 (03) ◽  
pp. 375-380
Author(s):  
Shazia Memon ◽  
Farzana Shiakh ◽  
Asadullah Makhdoom ◽  
S. M. Tahir

Deficiency of vitamin D is an emerging issue in children worldwide. It has beenobserved that all patients with vitamin D deficiency does not manifest clinical features or hyperparathyroidresponse. In this study we have evaluated the interaction of serum vitamin D level,parathyroid hormone (PTH) level and bone mineral density (BMD) in children. Objectives: Ourobjectives were to determine the frequency of Vitamin D deficiency in children and association oflow serum D level with serum parathyroid level and bone mineral density (BMD). Study Design:Descriptive cross sectional study. Period: June 2012 to May 2014. Setting: Pediatric and Orthopediatricout-patient departments. Material & Methods: A total of 500 children up to 15 yearswith low serum vitamin D level were enrolled to analyze the interaction of Serum vitamin D, PTHand BMD. Patients were divided in groups on the basis of serum PTH. We have categorize thedeficiency of Vitamin D on the basis of level of 25OHD. It was defined as severe (25OHD ≤ 5ng/ml), moderate (25OHD≤ 10 ng/ml) and mild (25OHD ≤ 20 ng/ml) and hyperparathyroidism(SHPT) was valued if level >65 pg/ml. All children with 25OH ≤ 20 ng/ml were included andassociation with SHPT and BMD were measured. Results: It has been observed that 30–40%of patients with moderate and severe deficiency of vitamin D respectively had shown increasedlevel of PTH. Bone mineral density has demonstrated decline pattern from PTH Quartile 1toQuartile 4 at all sites in children, with only minimal difference (decreasing trend) in serum25OHD levels between these quartiles. The critical level of parathyroid hormone beyond whichBMD going to decline is 35 pg/ml. No demonstrable difference has been observed in BMDwithin each PTH quartile according to categorization of Vitamin D Deficiency. Conclusions:Around 40% of the patients having low serum vitamin D level demonstrated SHPT. Regardingthe BMD levels, it begins to decreases at PTH levels currently well thought-out to be normal.So there is a need to re-define SHPT among different age groups considering the relationshiplinking PTH and BMD. This may also affect guidelines regarding vitamin d supplementation inpatients with vitamin D deficiency.


Sign in / Sign up

Export Citation Format

Share Document